{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:06:22Z","timestamp":1792872382344,"version":"4.5.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamaoncol.2020.3524","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T15:41:29Z","timestamp":1599147689000},"page":"1598","source":"Crossref","is-referenced-by-count":147,"title":["Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor\u2013Positive, <i>ERBB2<\/i>-Negative Metastatic Breast Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Sara M.","family":"Tolaney","sequence":"first","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Oncology Center, Hospital S\u00edrio-Liban\u00eas, Bras\u00edlia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Keenan","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Broad Institute of MIT and Harvard, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Trippa","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Vaz-Luis","sequence":"additional","affiliation":[{"name":"Unit Inserm 981, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerburg","family":"Wulf","sequence":"additional","affiliation":[{"name":"Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Spring","sequence":"additional","affiliation":[{"name":"Medical Oncology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Faye","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Andrews","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pittenger","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edward T.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Dillon","sequence":"additional","affiliation":[{"name":"Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Overmoyer","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer","family":"Van Allen","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Broad Institute of MIT and Harvard, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Mittendorf","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Breast Oncology Program, Dana-Farber\/Brigham and Women\u2019s Cancer Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"Krop","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"coi200060r1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer.","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"coi200060r2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"coi200060r3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.breast.2016.07.015","article-title":"The genomic landscape of breast cancer and its interaction with host immunity.","volume":"29","author":"Luen","year":"2016","journal-title":"Breast"},{"issue":"12","key":"coi200060r4","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-17-3452","article-title":"Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer.","volume":"24","author":"Rugo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"coi200060r5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","article-title":"Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study.","volume":"167","author":"Dirix","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"coi200060r6","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/JCO.2017.35.15_suppl.506","article-title":"Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2","volume":"35","author":"Nanda","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200060r7","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"coi200060r8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/bjc.2016.122","article-title":"In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumab.","volume":"114","author":"Ueda","year":"2016","journal-title":"Br J Cancer"},{"issue":"6","key":"coi200060r9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"coi200060r10","article-title":"Phase 1b\/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer","volume":"78","author":"Tolaney","year":"2018","journal-title":"Cancer Res"},{"issue":"11","key":"coi200060r11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.5858\/arpa.2015-0544-OA","article-title":"Development of a prototype immunohistochemistry assay to measure programmed death ligand-1 expression in tumor tissue.","volume":"140","author":"Dolled-Filhart","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"coi200060r12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"coi200060r13","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98811","article-title":"Frameshift events predict anti-PD-1\/L1 response in head and neck cancer.","volume":"3","author":"Hanna","year":"2018","journal-title":"JCI Insight"},{"issue":"8","key":"coi200060r14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium.","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"coi200060r15","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaoncol.2018.7147","article-title":"Current landscape of immunotherapy in breast cancer: a review.","volume":"5","author":"Adams","year":"2020","journal-title":"JAMA Oncol"},{"issue":"22","key":"coi200060r16","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"coi200060r17","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","article-title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers.","volume":"129","author":"Gruosso","year":"2019","journal-title":"J Clin Invest"},{"issue":"3","key":"coi200060r18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"coi200060r19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"coi200060r20","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1158\/1078-0432.CCR-19-1773","article-title":"Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts.","volume":"26","author":"Hutchinson","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"coi200060r21","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1093\/annonc\/mdy399","article-title":"Immunological differences between primary and metastatic breast cancer.","volume":"29","author":"Szekely","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"coi200060r22","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial.","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"issue":"15","key":"coi200060r23","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2020.38.15_suppl.1000","article-title":"KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer","volume":"38","author":"Cortes","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7757","key":"coi200060r24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic characterization of metastatic breast cancers.","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2769923\/jamaoncology_tolaney_2020_oi_200060_1619718159.01566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T18:30:24Z","timestamp":1619721024000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2769923"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.3524","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}